Atypical hyperplasia and early endometrial cancer: controversial aspects of terminology, classification, diagnosis and treatment. A review

Cover Page

Cite item

Full Text

Abstract

The incidence of endometrial atypical hyperplasia (EAH) and cancer (EC) shows a steady increase every year, which is associated with an increase in the prevalence of their risk factors, primarily the “nonsteroidal triad”: obesity, diabetes mellitus, and metabolic syndrome. In the context of the demographic crisis and the postponement of reproductive plans for the sake of self-realization, the issue of fertility preservation with a favorable prognosis in young patients with EAH and early stages of EC of the low-risk group becomes especially relevant. Significant advancements in classification approaches, with the isolation of EC molecular subtypes that determine prognosis, and in diagnostics, with the development of a new method of liquid-based cytology combined with ultrasound examination, help clearly stratify patients at the outpatient stage into a cohort suitable for organ-preserving therapy. A review of the results of systematic reviews and meta-analyses proves that to date, oral progestins or gonadotropin-releasing hormone agonists, the installation of a levonorgestrel-containing intrauterine system alone or in various combinations are justified alternatives to radical surgical treatment in patients with precancer and EC with minimal invasion of the myometrium according to expert-level ultrasound or magnetic resonance imaging, provided that complete drug pathomorphosis of foci is achieved with the prompt implementation of reproductive plans with the thorough monitoring by an obstetrician-gynecologist and a reproductive specialist.

About the authors

Natalia M. Podzolkova

Botkin City Clinical Hospital; Russian Medical Academy of Continuous Professional Education

Email: Yulia.sheveleva.97@mail.ru
ORCID iD: 0000-0001-8991-1369

D. Sci. (Med.), Prof.

Russian Federation, Moscow; Moscow

Alexey A. Karpov

Botkin City Clinical Hospital; Russian Medical Academy of Continuous Professional Education

Email: Yulia.sheveleva.97@mail.ru
ORCID iD: 0000-0002-5142-1302
SPIN-code: 9877-4166

D. Sci. (Med.)

Russian Federation, Moscow; Moscow

Sergey S. Lebedev

Botkin City Clinical Hospital; Russian Medical Academy of Continuous Professional Education

Email: Yulia.sheveleva.97@mail.ru
ORCID iD: 0000-0001-5366-1281
SPIN-code: 2736-0683

D. Sci. (Med.)

Russian Federation, Moscow; Moscow

Roman E. Kuznetsov

Botkin City Clinical Hospital; Russian Medical Academy of Continuous Professional Education

Email: Yulia.sheveleva.97@mail.ru
ORCID iD: 0000-0002-1061-4271

D. Sci. (Med.), Assoc. Prof.

Russian Federation, Moscow; Moscow

Yulia V. Denisova

Botkin City Clinical Hospital; Russian Medical Academy of Continuous Professional Education

Author for correspondence.
Email: Yulia.sheveleva.97@mail.ru
ORCID iD: 0000-0003-1753-0537

Cand. Sci. (Med.)

Russian Federation, Moscow; Moscow

Vladimir A. Alimov

Botkin City Clinical Hospital; Russian Medical Academy of Continuous Professional Education

Email: Yulia.sheveleva.97@mail.ru
ORCID iD: 0000-0002-6423-3917
SPIN-code: 6262-0720

Cand. Sci. (Med.)

Russian Federation, Moscow; Moscow

Andrey M. Danilov

Botkin City Clinical Hospital

Email: Yulia.sheveleva.97@mail.ru
ORCID iD: 0009-0009-1292-2807

Oncologist

Russian Federation, Moscow

Nikita P. Chizhikov

Botkin City Clinical Hospital

Email: Yulia.sheveleva.97@mail.ru
ORCID iD: 0009-0004-0584-8657

Department Head

Russian Federation, Moscow

Evgenij I. Zakurdaev

Botkin City Clinical Hospital

Email: Yulia.sheveleva.97@mail.ru
ORCID iD: 0000-0001-8613-9609
SPIN-code: 2404-1579

Cand. Sci. (Med.)

Russian Federation, Moscow

Larisa G. Sozaeva

Russian Medical Academy of Continuous Professional Education

Email: sozaewa@mail.ru
ORCID iD: 0000-0002-1793-5684
SPIN-code: 5452-8168

Cand. Sci. (Med.), Assoc. Prof.

Russian Federation, Moscow

Olga L. Glazkova

Russian Medical Academy of Continuous Professional Education

Email: Yulia.sheveleva.97@mail.ru
ORCID iD: 0000-0001-9324-2866

Cand. Sci. (Med.), Assoc. Prof.

Russian Federation, Moscow

Asel E. Karpova

Russian Medical Academy of Continuous Professional Education

Email: aselique@gmail.com
ORCID iD: 0000-0003-3415-8183
SPIN-code: 7732-7663

Cand. Sci. (Med.)

Russian Federation, Moscow

Irina P. Shabalova

Russian Medical Academy of Continuous Professional Education

Email: Yulia.sheveleva.97@mail.ru
ORCID iD: 0000-0002-7838-6279
SPIN-code: 7390-0085

D. Sci. (Med.), Prof.

Russian Federation, Moscow

Karine T. Kasoyan

Russian Medical Academy of Continuous Professional Education

Email: Yulia.sheveleva.97@mail.ru
ORCID iD: 0000-0002-8113-5251

Cand. Sci. (Med.), Assoc. Prof.

Russian Federation, Moscow

References

  1. Cancer Research UK. Uterine Cancer Statistics. 2015. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/uterine-cancer#heading-Zero. Accessed: 3 September 2025.
  2. Злокачественные новообразования в России в 2024 году (заболеваемость). Под ред. А.Д. Каприна. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2025 [Zlokachestvennye novoobrazovaniia v Rossii v 2024 godu (zabolevaemost'). Pod red. AD Kaprina. Moscow: MNIOI im. P.A. Gertsena − filial FGBU «NMITs radiologii» Minzdrava Rossii, 2025 (in Russian)].
  3. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Stat Fact Sheets: Endometrial Cancer. 2015. Available at: http://seer.cancer.gov/statfacts/html/corp.html. Accessed: 3 September 2025.
  4. Minig L, Franchi D, de Bernabe JV, Sideri M. Controversies of the hormonal conservative treatment of endometrial cancer. Gynecol Obstet Investig. 2013;75(3):145-51. doi: 10.1159/000349891
  5. Corzo C, Santillan NB, Westin SN, Ramirez PT. Updates on conservative management of endometrial cancer. J Minim Invasive Gynecol. 2018;25(2):308-13. doi: 10.1016/j.jmig.2017.07.022
  6. Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: Have they different risk factors? J Clin Oncol. 2013;31(20):2607-18. doi: 10.1200/JCO.2012.48.2596
  7. Post C, Stelloo E, Smit V, et al. Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer. JNCI J Natl Cancer Inst. 2021;113(9):1212-20. doi: 10.1093/jnci/djab029
  8. Contreras NA, Sabadell J, Verdaguer P, et al. Fertility-Sparing Approaches in Atypical Endometrial Hyperplasia and Endometrial Cancer Patients: Current Evidence and Future Directions. Int J Mol Sci. 2022;23(5):2531. doi: 10.3390/ijms23052531
  9. Schmeler KM, Lynch HT, Chen L, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006;354(3):261-9. doi: 10.1056/NEJMoa052627
  10. Uccella S, Cha SS, Melton LJ, et al. Risk factors for developing multiple malignancies in patients with endometrial cancer. Int J Gynecol Cancer. 2011;21(5):896-901. doi: 10.1097/IGC.0b013e318219711f
  11. Ravi RD, Kalra J, Srinivasan R, et al. A Randomized Clinical Trial of Levonorgestrel Intrauterine System with or Without Metformin For Treatment of Endometrial Hyperplasia Without Atypia in Indian Women. Asian Pac J Cancer Prev. 2021;22(3):983-9. doi: 10.31557/APJCP.2021.22.3.983
  12. Novikova OV, Nosov VB, Panov VA, et al. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer. Gynecol Oncol. 2021;161(1):152-9. doi: 10.1016/j.ygyno.2021.01.001
  13. American Cancer Society. Survival by Stage of Endometrial Cancer. 2018. Available at: https://www.cancer.org/cancer/endometrial-cancer/detection-diagnosis-staging/survival-rates.html. Accessed: 17.09.2025.
  14. Koh WJ, Abu-Rustum NR, Bean S, et al. Uterine neoplasms, Version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(2):170-99. doi: 10.6004/jnccn.2018.0006
  15. Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol. 2000;76(3):287-90. doi: 10.1006/gyno.1999.5580
  16. Кондриков Н.И., Силакова А.В. Гиперпластические изменения и предраковые состояния эндометрия: вопросы терминологии и классификации. Архив патологии. 2010;1:60-2. EDN:MBUWBD [Kondrikov NI, Silakova AV. Hyperplastic changes and precancerous endometrial: issues of terminology and classification. Arch Patol. 2010;72(1):60-2 (in Russian)].
  17. Rakha E, Wong SC, Soomro I, et al. Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: Institutional experience and review of literature. Am J Surg Pathol. 2012;36(11):1683-90. doi: 10.1097/PAS.0b013e31825dd4ff
  18. Lacey JV, Chia VM. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas. 2009;63(1):39-44. doi: 10.1016/j.maturitas.2009.02.005
  19. Cree IA, White VA, Indave BI, Lokuhetty D. Revising the WHO classification: female genital tract tumours. Histopathology. 2020;76(1):151-6. doi: 10.1111/his.13977
  20. Kurman R, Carcangiu M, Herrington C, Young R. World Health Organization Classification of Tumors of Female Reproductive Organs, 4th edn Lyon France: International Agency for Research on Cancer (IARC) Press, 2014. 307 p.
  21. Jarboe EA, Mutter GL. Endometrial intraepithelial neoplasia. Semin Diagn Pathol. 2010;27(4):215-25. doi: 10.1053/j.semdp.2010.09.007
  22. Khanna R, Rupala G, Khanna V. Endometrial Intraepithelial Neoplasia And Its Correlation With WHO Classified Endometrial Hyperplasia. Internet Journal of Pathology. 2010;1. Available at: https://ispub.com/IJPA/12/1/6890. Accessed: 12.09.2025.
  23. Sharma A, Lastra RR. Endometrial hyperplasia. PathologyOutlines.com website. Available at: https://www.pathologyoutlines.com/topic/uterusendometrialhyperplasiageneral.html. Accessed: 22.09.2025.
  24. Management of Endometrial Intraepithelial Neoplasia or Atypical Endometrial Hyperplasia: ACOG Clinical Consensus No. 5. Obstet Gynecol. 2023;142(3):735-44. doi: 10.1097/AOG.0000000000005297
  25. Cancer Genome Atlas Research N; Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73. doi: 10.1038/nature12113
  26. Talhouk A, McAlpine JN. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncol Res Pract. 2016;3:14. doi: 10.1186/s40661-016-0035-4
  27. Lv X, Guo L, Wang C. Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia. J Gynecol Oncol. 2024;35(3):e27. doi: 10.3802/jgo.2024.35.e27
  28. Concin N, Matias-Guiu X, Cibula D, et al. ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025. Lancet Oncol. 2025;26(8):e423-35. doi: 10.1016/S1470-2045(25)00167-6
  29. Созаева Л.Г., Шабалова И.П., Карпова А.Е., и др. Патология эндометрия: возможности цитологических исследований в диагностике. Эффективная фармакотерапия. 2024;20(45):6-10 [Sozaeva LG, Shabalova IP, Karpova AYe. Endometrial pathology: the possibilities of cytological studies in diagnosis. Effective Pharmacotherapy. 2024;20(45):6-10 (in Russian)]. doi: 10.33978/2307-3586-2024-20-45-6-10
  30. Карпова А.Е., Шабалова И.П., Касоян К.Т., и др. Значение цитологического исследования в диагностике патологии эндометрия. Медицинский алфавит. 2022;19:29-32 [Karpova AE, Shabalova IP, Kasoyan KT. Evaluation of exfoliative cytology in endometrial pathology. Medicinskij Alfavit. 2022;19:29-32 (in Russian)]. doi: 10.33667/2078-5631-2022-19-28-32
  31. Devic A, Vasiljevic M, Devic A. Endometrial intraepithelial neoplasia (EIN) in an endometrial polyp. Serbian Journal of Experimental and Clinical Research. 2015;16(4):343-6. doi: 10.1515/sjecr-2015-0042
  32. Hawez T, Bollino M, Lönnerfors C, Persson J. Endometrial Intraepithelial Neoplasia, Concurrent Endometrial Cancer and Risk for Pelvic Sentinel Node Metastases. Cancers (Basel). 2024;16(24):4215. doi: 10.3390/cancers16244215
  33. Georgescu TA, Cirstoiu M, Costache M, et al. Histopathological, immunohistochemical and therapeutical assessment of premalignant endometrial lesions in a hospital based series of cases. Maedica (Bucur). 2016;11(2):115-21.
  34. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. SEER Inquiry System – Question 20250001 Details. Available at: https://seer.cancer.gov/seer-inquiry/inquiry-detail/20250001/ Accessed: 25 September 2025.
  35. Lajer H, Elnegaard S, Christensen RD, et al. Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey. Acta Obstet Gynecol Scand. 2012;91(8):976-82. doi: 10.1111/j.1600-0412.2012.01438.x
  36. Kistner RW. Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium. Cancer. 1959;12:1106-22.
  37. Colombo N, Creutzberg C, Querleu D, et al. Appendix 5: Endometrial cancer: eUpdate published online 8 June 2017 (www.esmo.org/Guidelines/Gynaecological-Cancers). Ann Oncol. 2017;28(Suppl. 4):iv153-6. doi: 10.1093/annonc/mdx243
  38. Fernandez-Montoli ME, Sabadell J, Contreras Perez NA, et al. Fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Cochrane Database Syst Rev. 2025;7(7):CD013111. doi: 10.1002/14651858.CD013111.pub2
  39. Gallos ID, Yap J, Rajkhowa M, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012;207(4):266.e1-12. doi: 10.1016/j.ajog.2012.08.011
  40. Park JY, Kim DY, Kim JH, et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer. 2013;49(4):868-74. doi: 10.1016/j.ejca.2012.09.017
  41. Ferrari FA, Uccella S, Franchi M, et al. Performance of molecular classification in predicting oncologic outcomes of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Int J Gynecol Cancer. 2025;35(1):100016. doi: 10.1016/j.ijgc.2024.100016
  42. Zhang T, Zhang X, Peng P, Yang J. Fertility-sparing treatment in MSI-H/MMRd endometrial carcinoma or atypical endometrial hyperplasia: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2024;302:177-83. doi: 10.1016/j.ejogrb.2024.09.006
  43. Rodolakis A, Scambia G, Planchamp F, et al. ESGO/ESHRE/ESGE guidelines for the fertility-sparing treatment of patients with endometrial carcinoma. Int J Gynecol Cancer. 2023;33(2):208-22. doi: 10.1136/ijgc-2022-004047
  44. Патологоанатомическая диагностика опухолей человека. Руководство в двух томах. Под ред. Н.А. Краевского, А.В. Смольянникова. М.: Медицина, 1993. Т. 1, с. 130-58 [Patologoanatomicheskaia diagnostika opukholei cheloveka. Rukovodstvo v dvukh tomakh. Pod red. NA Kraevskogo, AV Smolyannikova. Moscow: Meditsina, 1993. Vol. 1, p. 130-58 (in Russian)].
  45. Wheeler DT, Bristow RE, Kurman RJ. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol. 2007;31(7):988-98. doi: 10.1097/PAS.0b013e31802d68ce
  46. Chen H, Lucas E, Strickland AL, et al. Specific Biomarker Expression Patterns in the Diagnosis of Residual and Recurrent Endometrial Precancers after Progestin Treatment: A Longitudinal Study. Am J Surg Pathol. 2020;44(10):1429-39. doi: 10.1097/PAS.0000000000001537
  47. Гиперплазия эндометрия. Клинические рекомендации. 2025. Режим доступа: https://cr.minzdrav.gov.ru/preview-cr/947_1 [Giperplaziia endometriia. Klinicheskie rekomendatsii. 2025. Available at: https://cr.minzdrav.gov.ru/preview-cr/947_1. Accessed: 10.10.2025 (in Russian)].
  48. Рак тела матки и саркомы матки. Клинические рекомендации. 2025. Режим доступа: https://cr.minzdrav.gov.ru/preview-cr/460_4 [Rak tela matki i sarkomi matki. 2025. Available at: https://cr.minzdrav.gov.ru/preview-cr/460_4. Accessed: 10.10.2025 (in Russian)].

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2025 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).